WHA Wereldhave N.V.

Werelhave results FY 2020

Werelhave results FY 2020

Delivering on our strategy in unprecedented markets

  • Direct result per share (DRPS) € 2.01, in line with guidance despite new lockdowns; € 0.50 dividend per share
  • Outlook trough DRPS 2022 reiterated at € 1.40-1.50
  • LifeCentral strategy realigned with new reality
  • Shopping center occupancy rate improved to 95.0%
  • € 270m refinancing deals and LTV almost stable at 46.3%*
  • Upgrade of Moody's outlook to 'Stable' expected
  • Success with Dutch disposals in 2021: In de Bogaard sold; last two properties in exclusivity phase

* Post-disposal shopping center In de Bogaard

Attachment



EN
12/02/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Wereldhave N.V.

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Aedifica: c.€29m new developments in Germany and Finland / GBL: €0.5bn equity investment in Rayner, an ophthalmic MedTech specialist / NN Group: Is consensus running ahead of a capital update with FY25 results? / Philips: Supportive update ahead of CMD / Proximus: Route Mobile 3Q26 shows lower revenues, better profitability / Staffing sector: French staffing: December better but January outlook weaker but perhaps better than number of temp outlook indicates / VAR Energi: Strong CMD target 400kpd...

Roy Külter ... (+2)
  • Roy Külter
  • Steven Boumans
 PRESS RELEASE

Wereldhave Full-year results 2025

Wereldhave Full-year results 2025 Direct result 2025 at € 1.86 per share, above guidance of € 1.80-1.85Occupancy rate at 98%, highest since 2013Like-for-like rental growth of +6%, driven by improved Dutch retail market and focus on other incomeDisposal of Dutch FSC Sterrenburg (€ 60m) at book value in December 2025Stable cost base despite portfolio growth and inflationTotal shareholder return 2025 of +51%Proposed dividend for 2025 at € 1.30 per share (+4%)Outlook 2026 direct result per share € 1.85-1.95 Attachment

ResearchPool Subscriptions

Get the most out of your insights

Get in touch